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Background: Ischemia-reperfusion injury involves free radical generation and poly-
morphonuclear neutrophil chemotaxis. Trimetazidine is an anti-ischemic drug that
restores the ability of the ischemic cells to produce energy and reduces the genera-
tion of oxygen-derived free radicals. We evaluated the effect of trimetazidine
against ischemia-reperfusion injury after lung transplantation.
Methods: Rat single lung transplantation was performed in 3 experimental groups
(n = 5): (1) the immediate transplantation group was defined as animals undergoing
transplantation immediately after harvest without treatment; (2) the ischemic con-
trol group was defined as animals undergoing transplantation after 18 hours of cold
(4°C) ischemia without treatment; and (3) the trimetazidine-treated group was
defined as animals undergoing transplantation after 18 hours of cold (4°C) ischemia
and donor and recipient treatment with 5 mg/kg intravenous trimetazidine 10 min-
utes before harvest and reperfusion, respectively. All donor lungs were flushed with
low-potassium dextran-glucose solution. After 2 hours of reperfusion, oxygenation
was measured, and lung tissue was frozen and assessed for adenosine triphosphate
content, myeloperoxidase activity, and thiobarbituric acid–reactive substances.
Peak airway pressure was recorded throughout the reperfusion period.
Results: The trimetazidine group showed significantly higher levels of adenosine
triphosphate content (1.73 ± 0.8 pmol vs 0.72 ± 0.2 pmol [ischemic control], P =
.008), better oxygenation (238.82 ± 113.9 mm Hg vs 89.39 ± 14.7 mm Hg
[ischemic control], P = .008), and reduced lipid peroxidation (1.28 ± 0.1 nmol/g vs
2.09 ± 0.4 nmol/g [ischemic control], P = .008). Adenosine triphosphate levels of
the trimetazidine group were comparable with those of the immediate transplanta-
tion group (1.73 ± 0.8 pmol vs 1.89 ± 0.5 pmol, respectively; P = .31). Peak airway
pressure and myeloperoxidase activity were comparable among groups.
Conclusion: Donor and recipient treatment with trimetazidine provided a significant
protection of the energy status, better oxygenation, and reduced lipid peroxidation
in this experimental model. Our data suggest that trimetazidine may be an impor-
tant adjunct to prolong ischemic time safely and to decrease lung ischemia-reper-
fusion injury.
Lung transplantation has become an established therapeutic pro-cedure for end-stage pulmonary disease. Ischemia-reperfusion(I/R) injury after lung transplantation continues to present apotentially life-threatening problem and remains a challenge inlung transplantation. Despite many improved strategies, as manyas 10% to 15% of the transplanted pulmonary allografts might
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experience severe graft dysfunction immediately after
implantation.1
Reperfusion of ischemic organs can result in tissue injury
that is manifested as microvascular and parenchymal cell
dysfunction.2 Reactive oxygen metabolites and polymor-
phonuclear leukocytes have been implicated in the patho-
physiology of reperfusion injury. Reactive oxygen metabo-
lites mediate the lipid peroxidation detected in postischemic
tissue and promote the formation of inflammatory media-
tors that recruit and activate polymorphonuclear leuko-
cytes.2 Although reperfusion is crucial for oxygen delivery
to ischemically injured tissues, tissue reoxygenation is
known to be detrimental because it allows the generation of
reactive oxygen metabolites, such as superoxide anions,
hydroxyl radicals, and hydrogen peroxides.3 Reactive oxy-
gen species stimulate the release and formation of inflam-
matory mediators with powerful chemotactic potential.
These molecules are a distress signal for the immune sys-
tem. They upregulate adhesion molecules on leukocytes and
endothelial cells and recruit leukocytes to the site of injury.
Moreover, I/R upregulates the expression of major histo-
compatibility complex molecules in clinical and experimen-
tal studies, rendering postischemic allografts more immuno-
genic and rejectable.2 For this reason, drugs that stabilize or
reverse I/R injury should improve the organ to be trans-
planted.
Trimetazidine (TMZ; 1-[2,3,4-trimethoxybenzyl] piper-
azine dihydrochloride) is an anti-ischemic agent known to
improve exercise tolerance and cardiac function in patients
with ischemic heart disease.4 Its anti-ischemic effect has
been experimentally assessed in various models, including
cell cultures, isolated and perfused organs, and in vivo mod-
els.5-11 In isolated cardiomyocyte models, TMZ treatment
resulted in increased cell resistance to hypoxic stress.6 In
isolated perfused heart models, it has been found that TMZ
protected myocardial energy transformation processes dur-
ing episodes of ischemia.7
The aim of this study was to determine the protective
effect of TMZ on post-transplant lung I/R injury, which was
assessed by means of blood oxygenation, peak airway pres-
sure, lung tissue adenosine triphosphate (ATP) content, lipid
peroxidation, and neutrophil accumulation.
Materials and Methods
Orthotopic single left lung transplantation was performed in male
Fischer (F344) rats weighing 280 to 300 g by use of a cuff tech-
nique for the anastomoses.12
All animals received humane care in accordance with the
“Guide for the Care and Use of Laboratory Animals” prepared by
the Institute of Laboratory Animal Resources, National Research
Council, and published by the National Academy Press, revised
1996. The study protocol was approved by the local animal study
committee.
Donor Procedure
Animals were anesthetized by means of intraperitoneal injection of
50 mg/kg sodium thiopental (Pentothal; Abbott AG, Baar,
Switzerland) and intubated through a tracheostomy with a 16-
gauge intravenous catheter. Animals were connected to a volume-
controlled ventilator (Harvard Rodent Ventilator, model 683;
Harvard Apparatus Co Inc, South Natick, Mass) and ventilated
with a fraction of inspired oxygen of 1, a tidal volume of 10 mL/kg
at 75 breaths/min, and a positive end-expiratory pressure of 3 cm
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Figure 1. Arterial blood gas (ABG) analysis of the groups. TMZ-treated group versus IC group, P = .008; ImTx group
versus IC group, P = .008; ImTx group versus TMZ group, P = .15.
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H2O. After this, a median laparosternotomy was performed, and
1000 IU/kg of heparin (Liquemin; Roche Pharma [Schweiz] AG,
Reinach, Switzerland) was injected into the inferior vena cava. For
the harvest of the heart-lung block, the inferior vena cava was
incised, the left atrial appendage was cut, and a 14-gauge cannula
was placed into the main pulmonary artery. The lungs were flushed
through this cannula with 20 mL of low-potassium dextran-glu-
cose (Perfadex; Xvivo Transplantation Systems AB, Gøteborg,
Sweden) at 4°C, which also contained 500 µg/L alprostadial
(prostaglandin E1, Prostin VR; Pharmacia & Upjohn, North
Peapack, NJ). After the lungs had been flushed, the intratracheal
tube was clamped to keep the lungs inflated during storage.
Hypothermic condition was maintained during the cuff (16-gauge)
placement into the pulmonary artery, pulmonary vein, and main
bronchus. The vessels or bronchus was drawn through the center of
the cuff, everted circumferentially around it, and secured with a 7-
0 silk ligature.
Recipient Procedure
Recipient animals were anesthetized and intubated as described for
donor animals. Anesthesia was maintained with 0.5% halothane
during the operation and reperfusion period. Ventilation parame-
ters were the same as in donor animals. For measuring the airway
pressure during the procedure, a 3-way tap was inserted between
the intratracheal tube and the ventilator circuit and connected to a
pressure transducer. A left thoracotomy was performed through the
fifth intercostal space. The left lung was mobilized by dividing the
pulmonary ligament. The hilum of the left lung was dissected, and
the pulmonary artery, pulmonary vein, and left main bronchus
were isolated. All 3 structures were clamped with microsurgical
aneurysm clamps. They were incised on their anterior aspect, and
the cuffs of the donor lung were placed into the equivalent recipi-
ent structures and fixed with a 6-0 polypropylene suture. The trans-
planted lung was inflated, and pulmonary vein and arterial clamps
were released. The thoracotomy was closed loosely. The recipient
animal was ventilated (with 99.5% oxygen and 0.5% halothane, a
tidal volume of 10 mL/kg at 75 breaths/min, and a positive end-
expiratory pressure of 3 cm H2O) for 2 hours.
Experimental Setting
Animals were randomized into 3 groups (n = 5 each): the immedi-
ate transplantation (ImTx) group, the ischemic control (IC) group,
and the TMZ-treated group. In the IC and TMZ groups, transplan-
tation was carried out after 18 hours of cold ischemia (4°C). There
was no treatment in the ImTx and IC groups. In the TMZ group,
donors received 5 mg/kg TMZ 10 minutes before harvest by means
of injection into the inferior vena cava, and the recipient received
5 mg/kg TMZ 10 minutes before reperfusion by means of injection
into the left superior vena cava. In the TMZ group, flush and
preservation solution contained 10–6 mol/L TMZ. Right donor
lungs (n = 5) were assessed for ATP, myeloperoxidase (MPO), and
thiobarbituric acid-reactive substances (TBARS) to obtain baseline
values in normal lungs.
MPO Assay
Quantitative MPO activity, as measured for neutrophil migration to
the graft, was determined as previously described.13 Frozen lung
tissue (100 mg) was homogenized in 1 mL of 0.5% hexade-
cyltrimethylammonium bromide, 5 mmol/L ethylenediamine tetra-
acetic acid, and 50 mmol/L potassium phosphate buffer (pH 6.2)
with a tissue grinder. The homogenate was centrifuged at 10,000g
for 15 minutes at 4°C. The supernatant was assayed for total solu-
ble protein by the method of Pierce Laboratories,14 as well as for
MPO activity. Enzyme activity was measured spectrophotometri-
cally. Ten milligrams of 5-fold supernatant was combined with 0.6
mL of Hanks bovine serum albumin, 0.5 mL of 100 mmol/L potas-
sium phosphate buffer (pH 6.2), 0.1 mL of 0.05% H2O2, and 0.1
mL of 1.25 mg/mL o-dianisidine. The reaction was stopped by
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Figure 2. Lung ATP content of the groups. TMZ-treated group versus IC group, P = .008; ImTx group versus IC group,
P = .008; ImTx group versus TMZ group, P = .31.
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addition of 1% NaN3 after 5 and 20 minutes at room temperature,
respectively. The optical density (OD) was measured at 460 nm
with a spectrophotometer (Kadas 100; Dr Lange, AG, Zurich
Switzerland). Color development from 5 to 20 minutes was linear.
Enzyme activity is expressed as the change in optical density
(∆OD) unit per milligram of tissue protein per minute.
TBARS
TBARS levels were measured according to the method of
Okhawa and coworkers15 in 10% wet weight per volume
homogenate to determine the lipid peroxidation in the graft tis-
sue. Aliquots (0.2 mL) of this homogenate were added to tubes
containing 0.2 mL of 8.1% sodium dodecyl sulfate, 1.5 mL of
20% acetic acid solution adjusted to 3.5 pH with NaOH, and 1.5
mL of 0.8% solution of thiobarbituric acid. The mixture was
brought to a volume of 4 mL by addition of distilled water, heat-
ed at 95°C for 60 minutes, and then cooled with tap water. One
milliliter of distilled water and 5 mL of butanol/pyridine (15:1)
was added (all chemicals from Fluka Chemie AG, Buchs,
Switzerland). The solution was centrifuged at 4000 rpm for 10
minutes. The absorbance of the upper layer was measured at 532
nm with a spectrophotometer (Kadas 100; Dr Lange, AG
Zurich). The TBARS levels were determined by reference to a
standard curve of 1,1,3,3-tetramethoxypropane (Sigma
Chemicals, Buchs, Switzerland), and the results were expressed
as nanomoles of malondialdehyde per gram of wet lung.
Lung ATP Content
Frozen lung tissue (100 mg) was homogenized in 0.9 mL of N-2-
hydroxyethylpiperazine-N-2-ethanesulfonic acid buffer. As an
extractant, 200 µL of trichloroacetic acid (1% final concentration,
Fluka AG) was used, and 100 µL of releasing agent was added to
this homogenate. The homogenate was centrifuged at 3000 rpm for
15 minutes at 4°C. The supernatant was removed and adjusted to
pH 7 by addition of 0.1 N NaOH. ATP concentration in the super-
natant was determined enzymatically with an ATP assay kit
(Calbiochem ATP Assay Kit, Calbiochem-Novobiochem
Corporation, San Diego, Calif). The results were expressed as
picomoles of ATP.
Graft Assessment
Peak airway pressure was recorded after intubation; after the chest
was entered; before reperfusion; at 1, 5, 10, and 15 minutes after
reperfusion; and then every 15 minutes thereafter. At the end of 2
hours of reperfusion, oxygenation of the graft was evaluated by
sampling the blood directly from the pulmonary vein of the trans-
planted lung by means of aspiration with a heparinized needle (29-
gauge) inserted distal to the anastomotic cuff.16 The transplanted
lung was excised, divided into 3 pieces, and put into the liquid
nitrogen and stored at –80°C for further evaluation of ATP,
TBARS, and MPO.
Statistical Analysis
Data analysis was performed with SPSS for Windows 8.0 (SPSS
Inc, Chicago, Ill). All data are expressed as mean values ± SD.
Because it was not possible to check for the normality of the
variables, with only 5 observations per group, we used nonpara-
metric procedures. We performed the Kruskal-Wallis test to
compare among the 3 groups. When a significant difference was
found, we then performed the Mann-Whitney test for compari-
son between 2 groups. Analysis of variance for repeated mea-
sures was used to evaluate the statistical difference between the
groups regarding the peak airway pressure over the 2-hour reper-
fusion period (which consists of 14 measurements). The normal
values were given for the purpose of comparison but were not
used in any testing procedures.
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Figure 3. TBARS levels of the groups. TMZ-treated group versus IC group, P = .008; ImTx group versus IC group, 
P = .008; ImTx group versus TMZ group, P = .84.
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Results
Blood Gas Analysis
Oxygenation 2 hours after graft reperfusion was higher in the
ImTx group (405.83 ± 142.6 mm Hg) than in the TMZ and
IC groups (238.82 ± 113.9 mm Hg and 89.39 ± 14.7 mm Hg,
respectively). The Kruskal-Wallis test showed significance
(P = .005) among the 3 groups, and the Mann-Whitney test
revealed a significant difference between the IC group versus
the TMZ group (P = .008) and the IC group versus the ImTx
group (P = .008). No statistical difference was found
between the ImTx and TMZ groups (P = .15, Figure 1).
Peak Airway Pressures
The analysis of variance for repeated measures with all
measurements made during the reperfusion period did not
show any significant differences among the groups (P =
.14). At the end of 2 hours of reperfusion, peak airway pres-
sure was 12.2 ± 1.3 mm Hg in the TMZ group, 13.2 ± 1.09
mm Hg in the IC group, and 10.8 ± 2.2 mm Hg in the ImTx
group. The Kruskal-Wallis test performed at this time point
did not show significance among the groups (P = .134).
Lung ATP Content
Lung ATP content in the normal lung was 8.5 ± 2.08
pmol of ATP. The TMZ group showed higher levels of
ATP content (1.73 ± 0.87 pmol of ATP) than in the IC
group (0.72 ± 0.2 pmol ATP) and comparable levels with
those of the ImTx group (1.89 ± 0.51 pmol of ATP). The
Kruskal-Wallis test revealed a significant difference
among the groups (P = .007). The Mann-Whitney test
showed a significant difference between the IC group
versus the TMZ group (P = .008) and the IC group ver-
sus the ImTx group (P = .008). No statistical difference
was found between the ImTx and TMZ groups (P = .31,
Figure 2).
TBARS
The normal lungs had a mean TBARS level of 0.14 ± 0.03
nmol of malondialdehyde per gram of wet lung. The amount
of lipid peroxidation was comparable between the TMZ and
ImTx groups (1.28 ± 0.14 nmol/g and 1.31 ± 0.15 nmol/g,
respectively), whereas the IC group had higher levels (2.09
± 0.42 nmol/g). The Kruskal-Wallis test showed a signifi-
cant difference among the groups (P = .009). The Mann-
Whitney test showed a significant difference between the IC
group versus the TMZ group (P = .008) and the IC group
versus the ImTx group (P = .008). The difference between
the ImTx and TMZ groups was not significant (P = .84,
Figure 3).
MPO Activity
MPO activity in the normal lungs was 0.5 ± 0.17 ∆OD ·
mg–1 · min–1. MPO activity in the ImTx, IC, and TMZ
groups was 1.68 ± 0.96 ∆OD · mg–1 · min–1, 2.81 ± 1.8
∆OD · mg–1 · min–1, and 2.49 ± 1.3 ∆OD · mg–1 · min–1,
respectively. The difference among the groups was not
significant, as determined with the Kruskal-Wallis test 
(P = .827, Figure 4).
Discussion
In this study with a rat single lung transplant model, we
showed that donor and recipient treatment with TMZ result-
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Figure 4. MPO activity of the groups. Kruskal-Wallis test result among the groups was not significant (P = .827).
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ed in significantly improved graft function. Energy status
was protected, and lipid peroxidation was reduced after 18
hours of cold storage and 2 hours of reperfusion. According
to our and others’ experience, 18 hours of cold ischemia is a
satisfactory time period to obtain severely injured lungs.17
The severity of I/R injury was examined 2 hours after the
start of reperfusion. This time point was chosen in the rat
model because it corresponds well with the early appear-
ance of reperfusion injury in the clinical setting.17
We used low-potassium dextran-glucose solution for
preservation and flush, which corresponds to our clinical
practice. The concentration of TMZ used in flush and
preservation solution was 10–6 mol/L. This concentration
has been shown to be effective in restoring ATP synthesis of
isolated mitochondria previously decreased by Ca2+ over-
load.5 Also, a previous study has demonstrated that higher
concentrations of TMZ exerted no protective effect.18
In anaerobic metabolism, instead of 38 mol of ATP, only
2 mol is produced, representing a 94% reduction of energy
production for essential cellular processes.19 Failure of ion
pumping with rapid loss of electrochemical gradients results
in translocation of ions, notably Ca2+. Free Ca2+ rapidly
accumulates and triggers many adverse effects, including
phospholipase activation.19 Another consequence of failed
ion pumping is that intracellular Na+ accumulates and K+ is
lost to the extracellular fluid. Cell swelling and interstitial
fluid accumulation produce edema and increase diffusion
distances, further compromising oxygen and substrate
delivery.19 The production of oxygen-derived free radicals
is considerably increased during tissue ischemia caused by
dissociation of oxidative phosphorylation, which results in
univalent reduction of oxygen, catabolism of ATP into
hypoxanthine and uric acid, and infiltration of damaged tis-
sues by polymorphonuclear leukocytes and phagocytosis.5
Various experimental studies have shown that TMZ has
preserved the intracellular concentrations of ATP and inhibit-
ed the extracellular leakage of potassium during cellular
ischemia. Additionally, it prevents excessive release of free
radicals, which are particularly toxic to phospholipid mem-
branes and are responsible for both the fall in the intracellular
ATP concentration and the extracellular leakage of potassi-
um. It also reduces intracellular accumulation of sodium and
calcium.20 Its mechanism of action is not fully understood,
but data indicate that it affects both metabolic functions and
ion permeabilities in mitochondria.21 It has been shown that
TMZ restored the ATP synthesis in isolated mitochondria pre-
viously exposed to Ca2+ overload.22 The formation of a giant
pore, called the mitochondrial transition pore, might be
involved, allowing the exchange of small solutes (<1500 d)
across the inner membrane.23 It has been stated that TMZ acts
on mitochondrial function in at least 2 different ways, as a
mitochondrial Ca2+ releaser when the giant pore is closed,
and by inducing its closure when the pore is open.21
TMZ is a cytoprotective drug that counteracts the meta-
bolic disorders occurring at the level of ischemic cells.24
The effect of TMZ on kidneys after 24 hours of cold storage
and subsequent reperfusion goes along with protection of
cells from acidosis during cold storage.24 With the 32P
nuclear magnetic resonance technique, it has been described
that TMZ counteracted the fall in ATP levels induced by
ischemia and favored the restoration of ATP levels during
reperfusion.25
In a rat liver model of I/R injury, TMZ lowered the
increase in liver enzymes and maintained higher concentra-
tions of hepatic ATP.26 In isolated rat liver mitochondria,
TMZ sustained the normal functions of mitochondria by
inhibiting mitochondrial swelling, the decrease in reduced
nicotinamide adenine dinucleotide phosphate level, and the
decrease in ATP synthesis.27
In our study a marked decrease in lung ATP level was
observed in the IC group, confirming that this index of func-
tion is rapidly and seriously affected by I/R. Lung grafts of
animals treated with TMZ and stored for 18 hours showed
ATP contents similar to those of lung grafts without storage.
We assume that the higher ATP content is not only the result
of better protected tissue by lesser I/R injury but also a
direct effect of ATP use itself. These results are in agree-
ment with those of the various other investigators.
Although TMZ is not known to have a direct effect on
neutrophils, the number of infiltrating neutrophils was sig-
nificantly lower in TMZ-treated rabbits in a myocardial I/R
model.10 Additionally, in a rat intestinal I/R injury model,
decreased MPO activity after TMZ therapy has been report-
ed.8 In contrast, in our study we were not able to show a dif-
ference in MPO activity among our study groups.
Free radical oxygen species can be measured indirectly
by using malondialdehyde as a marker. The colorimetric
reaction of thiobarbituric acid with malondialdehyde, a sec-
ondary product of lipid peroxidation, has been widely
adopted as a sensitive assay method for lipid peroxidation in
animal tissues.15 The high levels of malondialdehyde
observed in this and previous studies support the notion that
lipid peroxidation occurs during I/R injury. We have shown
that lipid peroxidation of the TMZ-treated group was sig-
nificantly less than that of the nontreated IC group. This
reduction in malondialdehyde levels is consistent with the
powerful antioxidant effect of TMZ. Significant reduction
of lipid peroxidation has also been reported by other inves-
tigators.3,8,28,29
In conclusion, in the rat single lung transplant model, we
found that donor and recipient treatment with TMZ
decreased the severity of I/R injury as shown by a signifi-
cant protection of the energy status, better oxygenation, and
reduced lipid peroxidation. Our data suggest that TMZ may
be an important adjunct to prolonging ischemic time safely
in lung transplantation.
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